National Academies Press: OpenBook
« Previous: 6 Moving Forward
Suggested Citation:"References." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

References

Abbott, A. 2013. Stem-cell ruling riles researchers. Nature 495(7442):418–419.

Abbott, A. 2014. Leaked files slam stem-cell therapy. Nature 505(7482):139–140.

Amariglio, N., A. Hirshberg, B. W. Scheithauer, Y. Cohen, R. Loewenthal, L. Trakhtenbrot, N. Paz, M. Koren-Michowitz, D. Waldman, L. Leider-Trejo, A. Toren, S. Constantini, and G. Rechavi. 2009. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Medicine 6(2):e1000029.

Arellano, M. 2012. The rise of stem cell therapies in Mexico: Inadequate regulation or unsuccessful oversight? Revista Redbioética/UNESCO 3(2):63–78.

ASRM (American Society for Reproductive Medicine). 2013. Definition of experimental procedures: A committee opinion. Fertility and Sterility 99(5):1197–1198.

Barclay, E. 2009. Stem-cell experts raise concerns about medical tourism. Lancet 373(9667):883–884.

Bianco, P. 2013. Don’t market stem-cell products ahead of proof. Nature 499(7458):255.

Bohgaki, T., T. Atsumi, and T. Koike. 2007. Multiple autoimmune diseases after autologous stem-cell transplantation. New England Journal of Medicine 357(26):2734–2736.

Caulfield, T., C. Rachul, and A. Zarzeczny. 2012. The evolution of policy issues in stem cell research: An international survey. Stem Cell Reviews 8(4):1037–1042.

CBER (Center for Biologics Evaluation and Research). 2011. Center for Biologics Evaluation and Research strategic plan, FY 2012–2016. http://www.fda.gov/downloads/aboutfda/centersoffices/cber/ucm266867.pdf (accessed March 25, 2014).

Chen, H., and H. Gottweis. 2013. Stem cell treatments in China: Rethinking the patient role in the global bio-economy. Bioethics 27(4):194–207.

Suggested Citation:"References." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

Connell, J. 2011. A new inequality?: Privatisation, urban bias, migration and medical tourism. Asia Pacific Viewpoint 52(3):260–271.

Cyranoski, D. 2009. Stem-cell therapy faces more scrutiny in China. Nature 459(7244):146–147.

Cyranoski, D. 2010. Korean deaths spark inquiry. Nature 468(7323):485.

Cyranoski, D. 2012. China’s stem-cell rules go unheeded. Nature 484(7393): 149–150.

Daley, G. Q. 2012. The promise and perils of stem cell therapeutics. Cell Stem Cell 10(6):740–749.

Dobkin, B. H., A. Curt, and J. Guest. 2006. Cellular transplants in China: Observational study from the largest human experiment in chronic spinal cord injury. Neurorehabilitation and Neural Repair 20(1):5–13.

Dominici, M., K. Le Blanc, I. Mueller, I. Slaper-Cortenbach, F. Marini, D. Krause, R. Deans, A. Keating, D. Prockop, and E. Horwitz. 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315–317.

EMA (European Medicines Agency). 2007. Regulation (EC) No. 1394/2007 of the European Parliament and of the Council. http://ec.europa.eu/health/files/eudralex/vol-1/reg_2007_1394/reg_2007_1394_en.pdf (accessed March 7, 2014).

FDA (U.S. Food and Drug Administration). 1997. Proposed approach to regulation of cellular and tissue-based products. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM062601.pdf (accessed March 11, 2014).

FDA. 2009. Regenerative Services, Inc. http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/complianceactivities/enforcement/untitledletters/ucm091991.htm (accessed March 6, 2014).

FDA. 2012. FDA warns about stem cell claims. http://www.fda.gov/forconsumers/consumerupdates/ucm286155.htm (accessed March 10, 2014).

FDA. 2013. Tissue reference group. http://www.fda.gov/biologicsbloodvaccines/tissuetissueproducts/regulationoftissues/ucm152857.htm (accessed March 6, 2014).

Fine, J. D., R. A. Eady, E. A. Bauer, J. W. Bauer, L. Bruckner–Tuderman, A. Heagerty, H. Hintner, A. Hovnanian, M. F. Jonkman, I. Leigh, J. A. McGrath, J. E. Mellerio, D. F. Murrell, H. Shimizu, J. Uitto, A. Vahlquist, D. Woodley, and G. Zambruno. 2008. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. Journal of the American Academy of Dermatology 58(6):931–950.

George, D. 2012. Mexico: A new legislation for stem cell therapies. Medical Tourism Magazine. http://www.medicaltourismmag.com/mexico-a-new-legislation-for-stem-cell-therapies (accessed April 24, 2014).

Suggested Citation:"References." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

Gunter, K. C., A. L. Caplan, C. Mason, R. Salzman, W. E. Janssen, K. Nichols, L. F. Bouzas, F. Lanza, B. L. Levine, J. E. Rasko, A. Shimosaka, and E. Horwitz. 2010. Cell therapy medical tourism: Time for action. Cytotherapy 12(8):965–968.

Hyun, I. 2010. Allowing innovative stem cell-based therapies outside of clinical trials: Ethical and policy challenges. Journal of Law, Medicine & Ethics 38(2):277–285.

Hyun, I., O. Lindvall, L. Ahrlund-Richter, E. Cattaneo, M. Cavazzana-Calvo, G. Cossu, M. De Luca, I. J. Fox, C. Gerstle, R. A. Goldstein, G. Hermeren, K. A. High, H. O. Kim, H. P. Lee, E. Levy-Lahad, L. Li, B. Lo, D. R. Marshak, A. McNab, M. Munsie, H. Nakauchi, M. Rao, H. M. Rooke, C. S. Valles, A. Srivastava, J. Sugarman, P. L. Taylor, A. Veiga, A. L. Wong, L. Zoloth, and G. Q. Daley. 2008. New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell 3(6):607–609.

Jabr, F. 2012. In the flesh: The embedded dangers of untested stem cell cosmetics. Scientific American, December 17. http://www.scientific.americancom/article/stem-cell-cosmetics (accessed March 10, 2014).

Kamao, H., M. Mandai, S. Okamoto, N. Sakai, A. Suga, S. Sugita, J. Kiryu, and M. Takahashi. 2014. Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Reports 2(2):205–218.

Kangas, B. 2010. Traveling for medical care in a global world. Medical Anthropology 29(4):344–362.

Lau, D., U. Ogbogu, B. Taylor, T. Stafinski, D. Menon, and T. Caulfield. 2008. Stem cell clinics online: The direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell 3(6):591–594.

Levine, A. D., and L. E. Wolf. 2012. The roles and responsibilities of physicians in patients’ decisions about unproven stem cell therapies. Journal of Law, Medicine & Ethics 40(1):122–134.

Master, Z., A. Zarzeczny, C. Rachul, and T. Caulfield. 2013. What’s missing?: Discussing stem cell translational research in educational information on stem cell “tourism.” Journal of Law, Medicine & Ethics 41(1):254–268.

Mendpara, S. D., C. Ustun, A. M. Kallab, F. M. Mazzella, P. A. Bilodeau, and A. P. Jillella. 2002. Cryptococcal meningitis following autologous stem cell transplantation in a patient with multiple myeloma. Bone Marrow Transplantation 30(4):259–260.

Moertel, C. G., T. R. Fleming, J. Rubin, L. K. Kvols, G. Sarna, R. Koch, V. E. Currie, C. W. Young, S. E. Jones, and J. P. Davignon. 1982. A clinical trial of amygdalin (laetrile) in the treatment of human cancer. New England Journal of Medicine 306(4):201–206.

Suggested Citation:"References." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

Nakamura, S., N. Takayama, S. Hirata, H. Seo, H. Endo, K. Ochi, K. Fujita, T. Koike, K. Harimoto, T. Dohda, A. Watanabe, K. Okita, N. Takahashi, A. Sawaguchi, S. Yamanaka, H. Nakauchi, S. Nishimura, and K. Eto. 2014. Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells. Cell Stem Cell 14(4):535–548.

NaRanong, A., and V. NaRanong. 2011. The effects of medical tourism: Thailand’s experience. Bulletin of the World Health Organization 89(5):336–344.

Nobel Media. 2013. Shinya Yamanaka––Facts. http://www.nobelprize.org/nobel_prizes/medicine/laureates/2012/yamanaka-facts.html (accessed March 7, 2014).

Ogbogu, U., C. Rachul, and T. Caulfield. 2013. Reassessing direct-to-consumer portrayals of unproven stem cell therapies: Is it getting better? Regenerative Medicine 8(3):361–369.

Parnell, S. 2013. NIB health fund to offer medical tourism. The Australian, October 26. http://www.theaustralian.com.au/news/health-science/nib-health-fund-to-offeroffer-medical-tourism/story-e6frg8y6-1226747206131# (accessed March 10, 2014).

Petersen, A., and K. Seear. 2011. Technologies of hope: Techniques of the online advertising of stem cell treatments. New Genetics and Society 30(4):329–346.

Petersen, A., K. Seear, and M. Munsie. 2013. Therapeutic journeys: The hopeful travails of stem cell tourists. Sociology of Health & Illness. doi:10.1111/1467-9566.12092.

Rachul, C. 2011. “What have I got to lose?”: An analysis of stem cell therapy patients’ blogs. Health Law Review 20(1):5–12.

Regenberg, A. C., L. A. Hutchinson, B. Schanker, and D. J. Mathews. 2009. Medicine on the fringe: Stem cell–based interventions in advance of evidence. Stem Cells 27(9):2312–2319.

Rowlings, P. A., S. F. Williams, K. H. Antman, K. K. Fields, J. W. Fay, E. Reed, C. J. Pelz, J. P. Klein, K. A. Sobocinski, M. J. Kennedy, C. O. Freytes, P. L. McCarthy, Jr., R. H. Herzig, E. A. Stadtmauer, H. M. Lazarus, A. L. Pecora, J. D. Bitran, S. N. Wolff, R. P. Gale, J. O. Armitage, W. P. Vaughan, G. Spitzer, and M. M. Horowitz. 1999. Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. Journal of the American Medical Association 282(14):1335–1343.

Ryan, K. A., A. N. Sanders, D. D. Wang, and A. D. Levine. 2010. Tracking the rise of stem cell tourism. Regenerative Medicine 5(1):27–33.

Scadden, D., and A. Srivastava. 2012. Advancing stem cell biology toward stem cell therapeutics. Cell Stem Cell 10(2):149–150.

Suggested Citation:"References." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

Seear, K., A. Petersen, M. Munsie, and R. Skinner. 2010. Hopeful journeys: Experiences of stem cell treatments offered outside Australia. Melbourne, Australia: School of Political and Social Inquiry, Monash University.

Takahashi, K., K. Tanabe, M. Ohnuki, M. Narita, T. Ichisaka, K. Tomoda, and S. Yamanaka. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861–872.

Taylor, P. L., R. A. Barker, K. G. Blume, E. Cattaneo, A. Colman, H. Deng, H. Edgar, I. J. Fox, C. Gerstle, L. S. Goldstein, K. A. High, A. Lyall, R. Parkman, F. J. Pitossi, E. D. Prentice, H. M. Rooke, D. A. Sipp, A. Srivastava, S. Stayn, G. K. Steinberg, A. J. Wagers, and I. L. Weissman. 2010. Patients beware: Commercialized stem cell treatments on the web. Cell Stem Cell 7(1):43–49.

Thirabanjasak, D., K. Tantiwongse, and P. S. Thorner. 2010. Angiomyelopro liferativeAngiomyeloproliferative lesions following autologous stem cell therapy. Journal of the American Society of Nephrology 21(7):1218–1222.

Tolar, J., and J. E. Wagner. 2012. Management of severe epidermolysis bullosa by haematopoietic transplant: Principles, perspectives and pitfalls. Experimental Dermatology 21(12):896–900.

Tolar, J., A. Ishida-Yamamoto, M. Riddle, R. T. McElmurry, M. Osborn, L. Xia, T. Lund, C. Slattery, J. Uitto, A. M. Christiano, J. E. Wagner, and B. R. Blazar. 2009. Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood 113(5):1167–1174.

Trounson, A., R. G. Thakar, G. Lomax, and D. Gibbons. 2011. Clinical trials for stem cell therapies. BMC Medicine 9(52).

Trounson, A., N. D. DeWitt, and E. G. Feigal. 2012. The alpha stem cell clinic: A model for evaluating and delivering stem cell-based therapies. Stem Cells Translational Medicine 1(1):9–14.

Vij, R., J. DiPersio, R. Brown, K. Trinkaus, C. Abboud, K. R. Meehan, G. Frenette, C. Freytes, L. T. Goodnough, H. Khoury, J. Ponnuri, and D. Adkins. 2000. Outcomes of high-dose chemotherapy and autologous stem cell transplant in isolated locally recurrent breast cancer: A multicenter evaluation. Bone Marrow Transplantation 26(9):947–953.

Young, F. E. 1988. The role of the FDA in the effort against AIDS. Public Health Reports 103(3):242–245.

Zarzeczny, A., C. Rachul, M. Nisbet, and T. Caulfield. 2010. Stem cell clinics in the news. Nature Biotechnology 28(12):1243–1246.

Suggested Citation:"References." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

This page intentionally left blank.

Suggested Citation:"References." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page 55
Suggested Citation:"References." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page 56
Suggested Citation:"References." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page 57
Suggested Citation:"References." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page 58
Suggested Citation:"References." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page 59
Suggested Citation:"References." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page 60
Next: Appendix A: Workshop Agenda »
Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research Get This Book
×
Buy Paperback | $40.00 Buy Ebook | $31.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Stem cells offer tremendous promise for advancing health and medicine. Whether being used to replace damaged cells and organs or else by supporting the body's intrinsic repair mechanisms, stem cells hold the potential to treat such debilitating conditions as Parkinson's disease, diabetes, and spinal cord injury. Clinical trials of stem cell treatments are under way in countries around the world, but the evidence base to support the medical use of stem cells remains limited. Despite this paucity of clinical evidence, consumer demand for treatments using stem cells has risen, driven in part by a lack of available treatment options for debilitating diseases as well as direct-to-consumer advertising and public portrayals of stem cell-based treatments. Clinics that offer stem cell therapies for a wide range of diseases and conditions have been established throughout the world, both in newly industrialized countries such as China, India, and Mexico and in developed countries such as the United States and various European nations. Though these therapies are often promoted as being established and effective, they generally have not received stringent regulatory oversight and have not been tested with rigorous trials designed to determine their safety and likely benefits. In the absence of substantiated claims, the potential for harm to patients - as well as to the field of stem cell research in general - may outweigh the potential benefits.

To explore these issues, the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research held a workshop in November 2013. Stem Cell Therapies summarizes the workshop. Researchers, clinicians, patients, policy makers, and others from North America, Europe, and Asia met to examine the global pattern of treatments and products being offered, the range of patient experiences, and options to maximize the well-being of patients, either by protecting them from treatments that are dangerous or ineffective or by steering them toward treatments that are effective. This report discusses the current environment in which patients are receiving unregulated stem cell offerings, focusing on the treatments being offered and their risks and benefits. The report considers the evidence base for clinical application of stem cell technologies and ways to assure the quality of stem cell offerings.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!